The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Guidelines for the diagnosis and management of multiple myeloma 2011
Abstract
In 2006 guidelines for the diagnosis and management of multiple myeloma were published (Smith et al, 2006). These current guidelines represent a major revision. The guideline has been split into two documents, focussing on the 'Diagnosis and management of multiple myeloma' and 'Supportive care in multiple myeloma 2011' (Snowden et al 2011). They are designed to be used together and to complement each other. The contents of 'Diagnosis and management of multiple myeloma' are listed below: Methodology, epidemiology and clinical presentation Diagnosis, prognostic factors and disease monitoring Imaging techniques Management of common medical emergencies in myeloma patients Myeloma bone disease Renal impairment Induction therapy including management of major toxicities and stem cell harvesting Management of refractory disease High dose therapy and autologous stem cell transplantation Allogeneic stem cell transplantation Maintenance therapy Management of relapsed myeloma including drugs in development Patient Information and Support The key areas that are covered comprehensively in the document entitled 'Guidelines for Supportive Care in Multiple Myeloma 2011' (Snowden et al 2011) are listed below: Anaemia Haemostasis and thrombosis issues Pain management Peripheral neuropathy Other symptom control – gastrointestinal, sedation/fatigue, mucositis Bisphosphonate-induced osteonecrosis of the jaw Complementary therapies End of life care The production of these guidelines involved the following steps: Establishment of working groups in the topic areas detailed above followed by review of key literature to 30th June 2010 including Cochrane database, Medline, internet searches and major conference reports. Development of key recommendations based on randomized, controlled trial evidence. In the absence of randomized data, recommendations were developed on the basis of literature review and a consensus of expert opinion. Involvement of patient advocacy through Myeloma UK. Review by UK Myeloma Forum (UKMF) Executive and British Committee for Standards in Haematology (BCSH) Committees. Review by a British Society for Haematology (BSH) sounding board. Levels of evidence and grades of recommendation are those of the US Agency for Healthcare Research and Quality (see Appendix I, Tables 1 and 2). In preparing these guidelines the authors have considered overall cost-effectiveness of recommended interventions as well as clinical efficacy data but formal health economic assessments have not been carried out. The annual incidence of myeloma in the UK is approximately 60–70 per million (http://info.cancerresearchuk.org/cancerstats/types/multiplemyeloma/incidence/index.htm). The overall prevalence is likely to be increasing given the recently published data demonstrating improved survival rates over the last decade (Kumar et al, 2008a; Brenner et al, 2009). The median age at presentation is approximately 70 years. Only 15% of patients are aged <60 years. Myeloma has a higher incidence in Afro-Caribbean ethnic groups than in Caucasians but there are few other distinctive epidemiological features. The majority of cases present de novo but it is now recognized that myeloma is preceded by an asymptomatic monoclonal gammopathy of undetermined significance (MGUS) phase in virtually all patients (Landgren et al, 2009). Presenting clinical features include symptoms of: Bone disease Impaired renal function Anaemia Hypercalcaemia Recurrent or persistent bacterial infection Hyperviscosity Other patients are diagnosed following the incidental detection of a raised erythrocyte sedimentation rate (ESR), plasma viscosity, serum protein or globulin. Patients with suspected myeloma require urgent specialist referral. Spinal cord compression, hypercalcaemia and renal failure are medical emergencies requiring immediate investigation and treatment. Investigation of a patient with suspected myeloma should include the screening tests indicated in Table I, followed by further tests to confirm the diagnosis. Electrophoresis of serum and concentrated urine should be performed, followed by immunofixation to confirm and type any M-protein present. Immunofixation and serum-free light chain (SFLC) assessment are indicated in patients where there is a strong suspicion of myeloma but in whom routine serum protein electrophoresis is negative (Pratt, 2008). Quantification of serum M-protein should be performed by densitometry of the monoclonal peak on electrophoresis; immunochemical measurement of total immunoglobulin (Ig) isotype level can also be used and is particularly useful for IgA and IgD M-proteins. Quantification of urinary total protein and light chain excretion can be performed directly on a 24 hour (h) urine collection or calculated on a random urine sample in relation to the urine creatinine. Quantification of SFLC levels and κ/λ ratio is an additional tool for the assessment of light chain production. The serum tests are particularly useful for diagno
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“Phase II data indicate improvement in response when dexamethasone is added in patients with a sub-optimal response to bortezomib alone (Richardson et al, 2003).”
BackgroundAttal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Self-citationReview of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447 · cited 1×
“…acid is the bisphosphonate of choice in the treatment of hypercalcaemia (grade A evidence; level I recommendation) 4.3 Cord compression Compression of the spinal cord from extramedullary foci of disease occurs in 5% of patients with myeloma during the course of their disease (Kyle et al, 2003).”
BackgroundInfluentialThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Skeletal complications of malignancy
Coleman, R. E. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.0.co;2-g · Cited by 1,502
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · cited 1×
“The largest randomized studies in this setting have employed the newer agents, and include the comparisons of bortezomib against dexamethasone (Richardson et al, 2005), and lenalidomide and dexamethasone against dexamethasone alone (Dimopoulos et al, 2007; Weber et al, 2007).”
BackgroundLandgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984 · cited 2×
“The IFM94 trial was the first randomized study comparing single and tandem transplants, reporting improved EFS (30 months vs. 25 months) and OS (58 months vs. 48 months; Attal et al, 2003).”
BackgroundRajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933 · cited 2×
“…dose steroids in the elderly or in patients with poor performance may be detrimental, with increased toxicity and a higher mortality rate in the short-term, and consideration should be given to the use of lower doses in this group (Ludwig et al, 2009a; Morgan et al, 2009; Rajkumar et al, 2010).”
BackgroundClinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
Shaughnessy, J. D., Zhan, F., Burington, B. E., Huang, Y., Colla, S., Hanamura, I., Stewart, J. P., Kordsmeier, B., Randolph, C., Williams, D. R., et al. (2007) · Blood · doi:10.1182/blood-2006-07-038430 · Cited by 914
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Fonseca, R., Bergsagel, P. L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, A. K., Morgan, G., Van Ness, B., Chesi, M., Minvielle, S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.174 · Cited by 886
Self-citationHideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Self-citationRosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 873
Facon, T., Mary, J. Y., Hulin, C., Benboubker, L., Attal, M., Pegourie, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 869
Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.558 · Cited by 858
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Palumbo, A., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G., San Miguel, J., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840
Self-citationSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68338-4 · Cited by 809
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationThalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053583 · Cited by 739
Multiple myeloma; a review of 26 cases.
Harnagel, E. E., Kleinberg, I., Kahlstrom, S. C., & Rhudy, F. V. (1957) · PubMed · Cited by 682
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
Attal, M., Harousseau, J.-L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Agha, I. Y., Bourhis, J.-H., Garderet, L., Pegourie, B., et al. (2006) · Blood · doi:10.1182/blood-2006-05-022962 · Cited by 667
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Orlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hajek, R., Spencer, A., San Miguel, J., Robak, T., Dmoszynska, A., Horvath, N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5460 · Cited by 645
Multiple Myeloma: Review of 869 Cases
Kyle, R. A. (1975) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)00115-6 · Cited by 640
Pérez-Persona, E., Vidriales, M.-B., Mateo, G., García-Sanz, R., Mateos, M.-V., de Coca, A. G., Galende, J., Martín-Nuñez, G., Alonso, J. M., de las Heras, N., et al. (2007) · Blood · doi:10.1182/blood-2007-05-088443 · Cited by 579
Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
Weber, D., Rankin, K., Gavino, M., Delasalle, K., & Alexanian, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.139 · Cited by 566
Moreau, P. (2002) · Blood · doi:10.1182/blood.v99.3.731 · Cited by 564
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., et al. (1997) · Blood · doi:10.1182/blood.v89.3.789 · Cited by 541
Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., et al. (2001) · Blood · doi:10.1182/blood.v98.2.492 · Cited by 541
Harousseau, J.-L., Attal, M., Avet-Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T., Casassus, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9158 · Cited by 532
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Richardson, P. G., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2007) · Blood · doi:10.1182/blood-2006-08-036947 · Cited by 513
Self-citationRawstron, A. C., Orfao, A., Beksac, M., Bezdickova, L., Brooimans, R. A., Bumbea, H., Dalva, K., Fuhler, G., Gratama, J., Hose, D., et al. (2008) · Haematologica · doi:10.3324/haematol.11080 · Cited by 513
Self-citationHIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
MCELWAIN, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 510
A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065464 · Cited by 501
Barlogie, B., Kyle, R. A., Anderson, K. C., Greipp, P. R., Lazarus, H. M., Hurd, D. D., McCoy, J., Moore, D. F., Dakhil, S. R., Lanier, K. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5807 · Cited by 495
Augustson, B. M., Begum, G., Dunn, J. A., Barth, N. J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J. A., & Drayson, M. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2086 · Cited by 488
Self-citationPaiva, B., Vidriales, M.-B., Cerveró, J., Mateo, G., Pérez, J. J., Montalbán, M. A., Sureda, A., Montejano, L., Gutiérrez, N. C., de Coca, A. G., et al. (2008) · Blood · doi:10.1182/blood-2008-05-159624 · Cited by 477
Pasquali, S., Maqueo, J. D., Vela, J. E., Kyle, R. A., Leong, T. L., Fritz, E., Suciu, S., PALVA, I. P., Oivanen, T. M., Corrado, C., et al. (1998) · Journal of Clinical Oncology · Cited by 470
Mateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70187-x · Cited by 458
Dispenzieri, A., Kyle, R. A., Katzmann, J. A., Therneau, T. M., Larson, D., Benson, J., Clark, R. J., Melton, L. J., Gertz, M. A., Kumar, S. K., et al. (2008) · Blood · doi:10.1182/blood-2007-08-108357 · Cited by 433
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
Drayson, M., Tang, L. X., Drew, R., Mead, G. P., Carr-Smith, H., & Bradwell, A. R. (2001) · Blood · doi:10.1182/blood.v97.9.2900 · Cited by 419
Mulligan, G., Mitsiades, C., Bryant, B., Zhan, F., Chng, W. J., Roels, S., Koenig, E., Fergus, A., Huang, Y., Richardson, P., et al. (2007) · Blood · doi:10.1182/blood-2006-09-044974 · Cited by 416
Maloney, D. G., Molina, A. J., Sahebi, F., Stockerl-Goldstein, K. E., Sandmaier, B. M., Bensinger, W., Storer, B., Hegenbart, U., Somlo, G., Chauncey, T., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2955 · Cited by 403
Jagannath, S., Durie, B. G. M., Wolf, J., Camacho, E., Irwin, D., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schenkein, D., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05540.x · Cited by 398
Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma
Lahtinen, R., Laakso, M., Palva, I., Elomaa, I., & Virkkunen, P. (1992) · The Lancet · doi:10.1016/0140-6736(92)93075-x · Cited by 385
Hulin, C., Facon, T., Rodon, P., Pegourie, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Salles, B., Eschard, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0948 · Cited by 381
Renal failure in multiple myeloma: reversibility and impact on the prognosis
Knudsen, L. M., Hjorth, M., Hippe, E., & Nordic Myeloma Study Group (2000) · European Journal of Haematology · doi:10.1034/j.1600-0609.2000.90221.x · Cited by 380
Allogeneic Bone Marrow Transplantation in Multiple Myeloma
Gahrton, G., Tura, S., Ljungman, P., Belanger, C., Brandt, L., Cavo, M., Facon, T., Granena, A., Gore, M., Gratwohl, A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251802 · Cited by 378
Reeder, C. B., Reece, D. E., Kukreti, V, Chen, C., Trudel, S., Hentz, J., Noble, B., Pirooz, N. A., Spong, J. E., Piza, J. G., et al. (2009) · Leukemia · doi:10.1038/leu.2009.26 · Cited by 372
Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2509 · Cited by 370
Cavo, M., Zamagni, E., Tosi, P., Tacchetti, P., Cellini, C., Cangini, D., de Vivo, A., Testoni, N., Nicci, C., Terragna, C., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0522 · Cited by 369
Garban, F., Attal, M., Michallet, M., Hulin, C., Bourhis, J. H., Yakoub-Agha, I., Lamy, T., Marit, G., Maloisel, F., Berthou, C., et al. (2006) · Blood · doi:10.1182/blood-2005-09-3869 · Cited by 368
Harousseau, J., Attal, M., Leleu, X. P., Troncy, J., Pegourié, B., Stoppa, A., Hulin, C., Benboubker, L., Fuzibet, J., Renaud, M., et al. (2006) · PubMed · Cited by 367
Renal Failure with the Use of Zoledronic Acid
(2003) · New England Journal of Medicine · doi:10.1056/nejm200310233491721 · Cited by 367
Primary dexamethasone treatment of multiple myeloma
Alexanian, R., Dimopoulos, M., Delasalle, K., & Barlogie, B. (1992) · Blood · doi:10.1182/blood.v80.4.887.887 · Cited by 366
Dimopoulos, M. A., Chen, C., Spencer, A., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 363
Palumbo, A., Bringhen, S., Liberati, A. M., Caravita, T., Falcone, A., Callea, V., Montanaro, M., Ria, R., Capaldi, A., Zambello, R., et al. (2008) · Blood · doi:10.1182/blood-2008-04-149427 · Cited by 358
Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Gastineau, D. A., Litzow, M. R., Fonseca, R., Roy, V, Rajkumar, S. V., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404801 · Cited by 351 · cited 1×
“Despite this, concerns have been raised about failure to harvest adequate stem cells after prolonged lenalidomide treatment and, as a result, it is now recommended that stem cells should be collected within 6 months of initiation of lenalidomide therapy (Kumar et al, 2007).”
BackgroundRajkumar, S. V., Rosiñol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1853 · Cited by 343
Gahrton, G., Svensson, H., Cavo, M., Apperley, J., Bacigalupo, A., Björkstrand, B., Bladé, J., Cornelissen, J., De Laurenzi, A., Facon, T., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02726.x · Cited by 340
Garcı́a-Sanz, R., Orfão, A., González, M., Tabernero, M. D., Bladé, J., Moro, M. J., Fernández-Calvo, J., Sanz, M. A., Pérez-Simón, J. A., Rasillo, A., et al. (1999) · Blood · doi:10.1182/blood.v93.3.1032 · Cited by 332
Plasma Exchange When Myeloma Presents as Acute Renal Failure: A Randomized, Controlled Trial
Clark, W. F., Stewart, A. K., Rock, G. A., Sternbach, M., Sutton, D. M., Barrett, B. J., Heidenheim, A. P., Garg, A. X., Churchill, D. N., & and the Canadian Apheresis Group (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-11-200512060-00005 · Cited by 332
Spencer, A., Prince, H. M., Roberts, A. W., Prosser, I. W., Bradstock, K. F., Coyle, L., Gill, D. S., Horvath, N., Reynolds, J., & Kennedy, N. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8573 · Cited by 332
Palumbo, A. (2004) · Blood · doi:10.1182/blood-2004-02-0408 · Cited by 329
Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., Crippa, C., Ciccone, G., Omedè, P., Ambrosini, M. T., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3463 · Cited by 319
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6802 · Cited by 317
Oakervee, H. E., Popat, R., Curry, N., Smith, P., Morris, C., Drake, M., Agrawal, S., Stec, J., Schenkein, D., Esseltine, D., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05519.x · Cited by 317
Self-citationA randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
McCloskey, MacLennan, Drayson, Chapman, Dunn, Kanis, & Adults, F. T. M. W. P. O. L. I. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00567.x · Cited by 314
Munshi, N. C., Anderson, K. C., Bergsagel, P. L., Shaughnessy, J., Palumbo, A., Durie, B., Fonseca, R., Stewart, A. K., Harousseau, J.-L., Dimopoulos, M., et al. (2011) · Blood · doi:10.1182/blood-2010-10-300970 · Cited by 311
Guidelines on the diagnosis and management of multiple myeloma 2005
Smith, A., Wisloff, F., Samson, D., & the UK Myeloma Forum, N. M. S. G. A. B. C. F. S. I. H. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05867.x · Cited by 311
VAD‐based regimens as primary treatment for multiple myeloma
Alexanian, R., Barlogie, B., & Tucker, S. (1990) · American Journal of Hematology · doi:10.1002/ajh.2830330203 · Cited by 307
Results of autologous stem cell transplant in multiple myeloma patients with renal failure
Badros, A., Barlogie, B., Siegel, E., Roberts, J., Langmaid, C., Zangari, M., Desikan, R., Shaver, M. J., Fassas, A., McConnell, S., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03033.x · Cited by 306
Durie, B. G. M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.037 · Cited by 300
O'Connor, O. A., Stewart, A. K., Vallone, M., Molineaux, C. J., Kunkel, L. A., Gerecitano, J. F., & Orlowski, R. Z. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0822 · Cited by 295
Serum test for assessment of patients with Bence Jones myeloma
Bradwell, A. R., Carr-Smith, H. D., Mead, G. P., Harvey, T. C., & Drayson, M. T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12457-9 · Cited by 285
Thalidomide and dexamethasone combination for refractory multiple myeloma
Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011132808904 · Cited by 283
van de Velde, H. J. K., Liu, X., Chen, G., Cakana, A., Deraedt, W., & Bayssas, M. (2007) · Haematologica · doi:10.3324/haematol.11534 · Cited by 283
Lahuerta, J. J., Mateos, M. V., Martínez-López, J., Rosiñol, L., Sureda, A., de la Rubia, J., García-Laraña, J., Martínez-Martínez, R., Hernández-García, M. T., Carrera, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9721 · Cited by 279
Lokhorst, H. M., van der Holt, B., Zweegman, S., Vellenga, E., Croockewit, S., van Oers, M. H., von dem Borne, P., Wijermans, P., Schaafsma, R., de Weerdt, O., et al. (2010) · Blood · doi:10.1182/blood-2009-05-222539 · Cited by 276
Johnson, W. J., Kyle, R. A., Pineda, A. A., O'Brien, P. C., & Holley, K. E. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.4.863 · Cited by 265
Rosiñol, L., Pérez-Simón, J. A., Sureda, A., de la Rubia, J., de Arriba, F., Lahuerta, J. J., González, J. D., Díaz-Mediavilla, J., Hernández, B., García-Frade, J., et al. (2008) · Blood · doi:10.1182/blood-2008-02-141598 · Cited by 264
Chanan-Khan, A. A., Kaufman, J. L., Mehta, J., Richardson, P. G., Miller, K. C., Lonial, S., Munshi, N. C., Schlossman, R., Tariman, J., & Singhal, S. (2007) · Blood · doi:10.1182/blood-2006-09-046409 · Cited by 256
Chen, N., Lau, H., Kong, L., Kumar, G., Zeldis, J. B., Knight, R., & Laskin, O. L. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007309563 · Cited by 248
Renal function in newly diagnosed multiple myeloma — A demographic study of 1353 patients
Knudsen, L. M., Hippe, E., Hjorth, M., Holmberg, E., & Westin, J. (1994) · European Journal of Haematology · doi:10.1111/j.1600-0609.1994.tb00190.x · Cited by 248
Cocks, K., Cohen, D., Wisløff, F., Sezer, O., Lee, S., Hippe, E., Gimsing, P., Turesson, I., Hajek, R., Smith, A., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.04.022 · Cited by 247
Soutar, R. L., Lucraft, H. H., Jackson, G., Reece, A. T., Bird, J. M., Low, E., & Samson, D. (2004) · Clinical Oncology · doi:10.1016/j.clon.2004.02.007 · Cited by 245
Self-citationMaintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
Berenson, J. R., Crowley, J. J., Grogan, T. M., Zangmeister, J., Briggs, A. D., Mills, G. M., Barlogie, B., & Salmon, S. E. (2002) · Blood · doi:10.1182/blood.v99.9.3163 · Cited by 240
Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma
Siegel, D. S., Desikan, K. R., Mehta, J., Singhal, S., Fassas, A., Munshi, N., Anaissie, E., Naucke, S., Ayers, D., Spoon, D., et al. (1999) · Blood · doi:10.1182/blood.v93.1.51 · Cited by 239
Glasmacher, A., Hahn, C., Hoffmann, F., Naumann, R., Goldschmidt, H., von Lilienfeld‐Toal, M., Orlopp, K., Schmidt‐Wolf, I., & Gorschlüter, M. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05914.x · Cited by 237
Myeloma bone disease: pathophysiology and management
Terpos, E., & Dimopoulos, M.-A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi235 · Cited by 235
Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance
Eleutherakis-Papaiakovou, V., Bamias, A., Gika, D., Simeonidis, A., Pouli, A., Anagnostopoulos, A., Michali, E., Economopoulos, T., Zervas, K., & Dimopoulos on behalf of the Greek M, M. A. (2007) · Leukemia & Lymphoma · doi:10.1080/10428190601126602 · Cited by 231
Terpos, E., Sezer, O., Croucher, P. I., García-Sanz, R., Boccadoro, M., San Miguel, J., Ashcroft, J., Bladé, J., Cavo, M., Delforge, M., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn796 · Cited by 230
Self-citationAutologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
Badros, A., Barlogie, B., Siegel, E., Morris, C., Desikan, R., Zangari, M., Fassas, A., Anaissie, E., Munshi, N., & Tricot, G. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02976.x · Cited by 226
Jagannath, S., Barlogie, B., Berenson, J. R., Singhal, S., Alexanian, R., Srkalovic, G., Orlowski, R. Z., Richardson, P. G., Anderson, J., Nix, D., et al. (2005) · Cancer · doi:10.1002/cncr.20888 · Cited by 222
Hjorth, M., Hellquist, L., Holmberg, E., Magnusson, B., Rödjer, S., & Westin, J. (1993) · European Journal of Haematology · doi:10.1111/j.1600-0609.1993.tb00148.x · Cited by 220 · cited 1×
“Early intervention in patients with asymptomatic myeloma is not required (Hjorth et al, 1993; Riccardi et al, 2000) although chemotherapy may be considered in patients with a rising Mprotein concentration in the absence of ROTI.”
BackgroundFonseca, R., Van Wier, S. A., Chng, W. J., Ketterling, R., Lacy, M. Q., Dispenzieri, A., Bergsagel, P. L., Rajkumar, S. V., Greipp, P. R., Litzow, M. R., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404403 · Cited by 213
Ludwig, H., Hajek, R., Tóthová, E., Drach, J., Adam, Z., Labar, B., Egyed, M., Spicka, I., Gisslinger, H., Greil, R., et al. (2009) · Blood · doi:10.1182/blood-2008-07-169565 · Cited by 208
Stewart, A. K., Bergsagel, P. L., Greipp, P. R., Dispenzieri, A., Gertz, M. A., Hayman, S. R., Kumar, S., Lacy, M. Q., Lust, J. A., Russell, S. J., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404516 · Cited by 207
Guidelines for supportive care in multiple myeloma 2011
Snowden, J. A., Ahmedzai, S. H., Ashcroft, J., D’Sa, S., Littlewood, T., Low, E., Lucraft, H., Maclean, R., Feyler, S., Pratt, G., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08574.x · Cited by 206
Self-citationImmunomodulation by thalidomide and thalidomide analogues
Corral, L. G., & Kaplan, G. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.2008.i107 · Cited by 202
Stewart, A. K., Vescio, R., Schiller, G., Ballester, O., Noga, S., Rugo, H., Freytes, C., Stadtmauer, E., Tarantolo, S., Sahebi, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.17.3771 · Cited by 199
Serum free light chains for monitoring multiple myeloma
Mead, G. P., Carr‐Smith, H. D., Drayson, M. T., Morgan, G. J., Child, J. A., & Bradwell, A. R. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05045.x · Cited by 196
Self-citationLow-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.
Palumbo, A., Giaccone, L., Bertola, A., Pregno, P., Bringhen, S., Rus, C., Triolo, S., Gallo, E., Pileri, A., & Boccadoro, M. (2001) · PubMed · Cited by 191
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
Gore, M. E., Viner, C., Meldrum, M., Bell, J., Milan, S., Zuiable, A., Slevin, M., Selby, P. J., Clark, P. I., Millar, B., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91548-1 · Cited by 190
Samson, D., Newland, A., Kearney, J., Joyner, M., Mitchell, T., Barrett, A. J., Gaminara, E., Van De Pette, J., McCarthy, D., Aston, L., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91549-3 · Cited by 187
San-Miguel, J. F., Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405087 · Cited by 185
Self-citationAvet-Loiseau, H., Garand, R., Lodé, L., Harousseau, J.-L., & Bataille, R. (2003) · Blood · doi:10.1182/blood-2002-08-2436 · Cited by 185
Musto, P., Petrucci, M. T., Bringhen, S., Guglielmelli, T., Caravita, T., Bongarzoni, V., Andriani, A., D'Arena, G., Balleari, E., Pietrantuono, G., et al. (2008) · Cancer · doi:10.1002/cncr.23783 · Cited by 185
Kröger, N., Sayer, H. G., Schwerdtfeger, R., Kiehl, M., Nagler, A., Renges, H., Zabelina, T., Fehse, B., Ayuk, F., Wittkowsky, G., et al. (2002) · Blood · doi:10.1182/blood-2002-04-1150 · Cited by 185
Dimopoulos, M. A., Palumbo, A., Delasalle, K. B., & Alexanian, R. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb05114.x · Cited by 184
Niesvizky, R., Jayabalan, D. S., Christos, P. J., Furst, J. R., Naib, T., Ely, S., Jalbrzikowski, J., Pearse, R. N., Zafar, F., Pekle, K., et al. (2008) · Blood · doi:10.1182/blood-2007-05-090258 · Cited by 184
Crawley, C., Iacobelli, S., Björkstrand, B., Apperley, J. F., Niederwieser, D., Gahrton, G., & for the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2007) · Blood · doi:10.1182/blood-2006-07-036848 · Cited by 181
McCloskey, E. V., Dunn, J. A., Kanis, J. A., MacLennan, I. C. M., Drayson, M. T., & the Medical Research Council Working Party on Leukaemia in Adults (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02851.x · Cited by 181
Effect of daily etidronate on the osteolysis of multiple myeloma.
Belch, A. R., Bergsagel, D. E., Wilson, K., O'Reilly, S., Wilson, J., Sutton, D., Pater, J., Johnston, D., & Zee, B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.8.1397 · Cited by 178
Lokhorst, H. M., Wu, K., Verdonck, L. F., Laterveer, L. L., van de Donk, N. W. C. J., van Oers, M. H. J., Cornelissen, J. J., & Schattenberg, A. V. (2004) · Blood · doi:10.1182/blood-2003-11-3862 · Cited by 178
Lee, C.-K., Barlogie, B., Munshi, N., Zangari, M., Fassas, A., Jacobson, J., van Rhee, F., Cottler-Fox, M., Muwalla, F., & Tricot, G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.055 · Cited by 175
Palumbo, A., Gay, F., Falco, P., Crippa, C., Montefusco, V., Patriarca, F., Rossini, F., Caltagirone, S., Benevolo, G., Pescosta, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7561 · Cited by 173
Srkalovic, G., Cameron, M. G., Rybicki, L., Deitcher, S. R., Kattke‐Marchant, K., & Hussein, M. A. (2004) · Cancer · doi:10.1002/cncr.20405 · Cited by 172
Dimopoulos, M. A., Richardson, P. G., Schlag, R., Khuageva, N. K., Shpilberg, O., Kastritis, E., Kropff, M., Petrucci, M. T., Delforge, M., Alexeeva, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2232 · Cited by 172
Roussel, M., Moreau, P., Huynh, A., Mary, J.-Y., Danho, C., Caillot, D., Hulin, C., Fruchart, C., Marit, G., Pégourié, B., et al. (2010) · Blood · doi:10.1182/blood-2009-06-229658 · Cited by 171
Kastritis, E., Anagnostopoulos, Α., Ρούσσου, Μ., Gika, D., Matsouka, C., Barmparousi, D., Grapsa, I., Psimenou, E., Bamias, A., & Dimopoulos, M. A. (2007) · Haematologica · doi:10.3324/haematol.10759 · Cited by 169
Mohty, B., El-Cheikh, J., Yakoub-Agha, I., Moreau, P., Harousseau, J.-L., & Mohty, M. (2010) · Haematologica · doi:10.3324/haematol.2009.012674 · Cited by 167
Fritz, E., & Ludwig, H. (2000) · Annals of Oncology · doi:10.1023/a:1026548226770 · Cited by 163
García-Sanz, R., González-Porras, J. R., Hernández, J. M., Polo-Zarzuela, M., Sureda, A., Barrenetxea, C., Palomera, L., López, R., Grande-García, C., Alegre, A., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159
Morris, C. L., Siegel, E., Barlogie, B., Cottler‐Fox, M., Lin, P., Fassas, A., Zangari, M., Anaissie, E., & Tricot, G. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04107.x · Cited by 159
Menssen, H. D., Sakalová, A., Fontana, A., Herrmann, Z., Boewer, C., Facon, T., Lichinitser, M. R., Singer, C. R. J., Euller-Ziegler, L., Wetterwald, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.032 · Cited by 159
Belch, A. R., Shelley, W. E., Bergsagel, D. E., Wilson, K. S., Klimo, P., White, D., & Willan, A. R. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.17 · Cited by 155
Bird, J. M., Behrens, J., Westin, J., Turesson, I., Drayson, M. T., Beetham, R., D’Sa, S., Soutar, R. L., Waage, A., Gulbrandsen, N., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07807.x · Cited by 153
Self-citationDimopoulos, M. A., Hamilos, G., Zomas, A., Gika, D., Efstathiou, E., Grigoraki, V., Poziopoulos, C., Xilouri, I., Zorzou, M. P., Anagnostopoulos, N. I., et al. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200326 · Cited by 150
Albarracín, F., & Fonseca, R. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.01.005 · Cited by 142
Bisphosphonates in multiple myeloma
Djulbegović, B., Wheatley, K., Ross, H. F., Clark, O. A. C., Bos, G. M. J., Goldschmidt, H., Cremer, F. W., Alsina, M., & Glasmacher, A. G. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003188 · Cited by 141
Kropff, M. H., Lang, N., Bisping, G., Dominé, N., Innig, G., Hentrich, M., Mitterer, M., Südhoff, T., Fenk, R. R., Straka, C., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04473.x · Cited by 140
Kapoor, P., Kumar, S. K., Fonseca, R., Lacy, M. Q., Witzig, T. E., Hayman, S. R., Dispenzieri, A. A., Buadi, F. K., Bergsagel, P. L., Gertz, M. A., et al. (2009) · Blood · doi:10.1182/blood-2009-01-202010 · Cited by 136
Kumar, S. K., Dingli, D., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Buadi, F. K., Rajkumar, S. V., Litzow, M. R., & Gertz, M. A. (2008) · American Journal of Hematology · doi:10.1002/ajh.21191 · Cited by 128
Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure
Knudsen, L. M., Nielsen, B., Gimsing, P., & Geisler, C. H. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00446.x · Cited by 125
Riccardi, A., Mora, O., Tinelli, C., Valentini, D., Brugnatelli, S., Spanedda, R., Paoli, A. D., Barbarano, L., Stasi, M., Giordano, M., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1087 · Cited by 124
Mark, T. M., Stern, J. L., Furst, J. R., Jayabalan, D. S., Zafar, F., LaRow, A., Pearse, R. N., Harpel, J. G., Shore, T. B., Schuster, M. W., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.04.008 · Cited by 122
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
Brenner, H., Gondos, Á., & Pulte, D. D. (2009) · Haematologica · doi:10.3324/haematol.13782 · Cited by 120
Rosiñol, L., Oriol, A., Mateos, M., Sureda, A. M., García-Sánchez, P., Gutierrez, N. C., Alegre, A. M., Lahuerta, J. J., de la Rubia, J., Herrero, C. P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3323 · Cited by 118
Kröger, N. M., Shimoni, A., Zagrivnaja, M., Ayuk, F. A., Lioznov, M. V., Schieder, H., Renges, H., Fehse, B., Zabelina, T., Nagler, A., et al. (2004) · Blood · doi:10.1182/blood-2004-05-2031 · Cited by 117
Guidelines for the use of imaging in the management of myeloma
D’Sa, S., Abildgaard, N., Tighe, J. E., Shaw, P. J., & Hall-Craggs, M. A. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06491.x · Cited by 116
Self-citationAre myeloma patients with renal failure candidates for autologous stem cell transplantation?
Miguel, J. F. S., Lahuerta, J. J., García‐Sánz, R., Alegre, A. M., Bladé, J., Martínez, R. M. C., García‐Laraña, J., de la Rubia, J., Sureda, A. M., Vidal, M. J., et al. (2000) · The Hematology Journal · doi:10.1038/sj.thj.6200003 · Cited by 116
Early myeloablative therapy for multiple myeloma
Alexanian, R., Dimopoulos, M. A., Hester, J. P., Delasalle, K. B., & Champlin, R. E. (1994) · Blood · doi:10.1182/blood.v84.12.4278.bloodjournal84124278 · Cited by 115
Stadtmauer, E. A., Weber, D. M., Niesvizky, R., Belch, A., Prince, M. H., Miguel, J. F. S., Facon, T. T. F., Olesnyckyj, M., Yu, Z., Zeldis, J. B., et al. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01257.x · Cited by 114
Kyriakou, C. A., Thomson, K. J., D’Sa, S., Flory, A. J., Hanslip, J., Goldstone, A. H., & Yong, K. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05521.x · Cited by 114
Self-citationTosi, P., Zamagni, E., Cellini, C., Cangini, D., Tacchetti, P., Tura, S., Baccarani, M., & Cavo, M. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00272.x · Cited by 112
Kumar, A., Kharfan‐Dabaja, M. A., Glasmacher, A. G., & Djulbegović, B. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn439 · Cited by 112
Davies, F. E., Forsyth, P. D., Rawstron, A. C., Owen, R. G., Pratt, G., Evans, P., Richards, S. J., Drayson, M. T., Smith, G., Selby, P. J., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02530.x · Cited by 111
Self-citationRotta, M., Storer, B. E., Sahebi, F., Shizuru, J. A., Bruno, B., Lange, T., Agura, E. D., McSweeney, P. A., Pulsipher, M. A., Hari, P., et al. (2008) · Blood · doi:10.1182/blood-2008-07-170746 · Cited by 108
Ebbing, R. M. (1970) · The Lancet · doi:10.1016/s0140-6736(70)92052-0 · Cited by 108
Podocyte injury associated glomerulopathies induced by pamidronate
Barri, Y. M., Munshi, N. C., Sukumalchantra, S., Abul‐Ezz, S. R., Bonsib, S. M., Wallach, J., & Walker, P. D. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00426.x · Cited by 104
Neurological toxicity of long‐term (>1 yr) thalidomide therapy in patients with multiple myeloma
Tosi, P., Zamagni, E., Cellini, C., Plasmati, R., Cangini, D., Tacchetti, P., Perrone, G., Pastorelli, F., Tura, S., Baccarani, M., et al. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00382.x · Cited by 98
Mehta, J. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp320 · Cited by 98
Kumar, S. K., Lacy, M. Q., Dispenzieri, A. A., Rajkumar, S. V., Fonseca, R., Geyer, S. M., Allmer, C., Witzig, T. E., Lust, J. A., Greipp, P. R., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704545 · Cited by 96
The evolving use of serum free light chain assays in haematology
Pratt, G. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07079.x · Cited by 94
Self-citationDrayson, M. T., Begum, G., Basu, S., Makkuni, S., Dunn, J., Barth, N. J., & Child, J. A. (2006) · Blood · doi:10.1182/blood-2006-03-008953 · Cited by 94
Thalidomide and a Thalidomide Analogue Drug Costimulate Virus‐Specific CD8+T Cells In Vitro
Haslett, P. A. J., Hanekom, W. A., Muller, G. W., & Kaplan, G. (2003) · The Journal of Infectious Diseases · doi:10.1086/368126 · Cited by 93
Lee, C.-K., Badros, A. Z., Barlogie, B., Morris, C., Zangari, M., Fassas, A., van Rhee, F., Cottler‐Fox, M., Jacobson, J. L., Thertulien, R., et al. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(02)01010-x · Cited by 91
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
Miguel, J. F. S., Harousseau, J., Joshua, D., & Anderson, K. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2546 · Cited by 90
Eriksson, T., Höglund, P., Turesson, I., Waage, A., Don, B. R., Vu, J. T., Scheffler, M. R., & Kaysen, G. A. (2003) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357022241 · Cited by 89
BONE DISEASE IN MULTIPLE MYELOMA
Croucher, P. I., & Apperley, J. F. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01082.x · Cited by 88
Mateos, M., Hernández‐Rivas, J. M., Hernández, M., Gutierrez, N. C., Palomera, L., Fuertes, M., Garcia-Sanchez, P., Lahuerta, J. J., de la Rubia, J., Terol, M. J., et al. (2008) · Haematologica · doi:10.3324/haematol.12106 · Cited by 86
Shustik, C., Belch, A. R., Robinson, S., Rubin, S. H., Dolan, S., Kovacs, M. J., Grewal, K. S., Walde, D., Barr, R., Wilson, J., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06405.x · Cited by 83
Ρούσσου, Μ., Kastritis, E., Migkou, M., Psimenou, E., Grapsa, I., Matsouka, C., Barmparousi, D., Terpos, E., & Dimopoulos, M. A. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190801930506 · Cited by 82
McCarthy, P., Owzar, K., Anderson, K. C., Hofmeister, C. C., Hassoun, H., Hurd, D. D., Stadtmauer, E. A., Giralt, S., Hárs, V., Linker, C. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8017 · Cited by 82
Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of age
Reece, D. E., Bredeson, C., Pérez, W. S., Jagannath, S., Zhang, M.-J., Ballen, K., Elfenbein, G. J., Freytes, C. O., Gale, R. P., Gertz, M. A., et al. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704288 · Cited by 80
Pönisch, W., Rozanski, M. J., Goldschmidt, H., Hoffmann, F. A., Boldt, T., Schwarzer, A., Ritter, U., Rohrberg, R., Schwalbe, E., Uhlig, J., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07076.x · Cited by 80
Vogel, C. L., Yanagihara, R. H., Wood, A. J., Schnell, F. M., Henderson, C., Kaplan, B. H., Purdy, M. H., Orlowski, R., Decker, J. L., Lacerna, L. V., et al. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-687 · Cited by 76
Hicks, L. K., Haynes, A. E., Reece, D. E., Walker, I., Herst, J. A., Meyer, R. M., & Imrie, K. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.02.003 · Cited by 73
Zervas, K., Mihou, D., Katodritou, E., Pouli, A. G., Mitsouli, C., Anagnostopoulos, Α., Delibasi, S., Kyrtsonis, M., Anagnostopoulos, N., Terpos, E., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm178 · Cited by 71
LeBlanc, R., Montminy-Métivier, S., Bélanger, R., Busque, L., Fish, D., Roy, D.-C., Kassis, J., Boileau, J., Lavallee, R., Belanger, D., et al. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703253 · Cited by 70
Al‐Quran, S. Z., Yang, L., Magill, J. M., et al. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.04.010 · Cited by 68
14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia
Avet‐Loiseau, H., Garand, R., Lodé, L., Robillard, N., & Bataille, R. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50053 · Cited by 68
Mohty, M., Boiron, J.-M., Damaj, G. L., Michallet, A., Bay, J., Faucher, C., Perreau, V., Bilger, K., Coso, D., Stoppa, A., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704531 · Cited by 67
Stewart, A. K., Chen, C. I., Howson‐Jan, K., White, D. J., Roy, J., Kovacs, M. J., Shustik, C., Sadura, A., Shepherd, L. E., Ding, K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1106 · Cited by 67
Sonneveld, P., van der Holt, B., Schmidt‐Wolf, I. G. H., Bertsch, U., el Jarari, L., Salwender, H.-J., Zweegman, S., Vellenga, E., Schubert, J. E. A., Blau, I. W., et al. (2008) · Blood · doi:10.1182/blood.v112.11.653.653 · Cited by 66
Bird, J. M., Fuge, R., Sirohi, B., Apperley, J. F., Hunter, A., Snowden, J. A., Mahendra, P., Milligan, D. W., Byrne, J., Littlewood, T. J., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06191.x · Cited by 62
Self-citationMyelomatosis: Comparison of Melphalan and Cyclophosphamide Therapy
(1971) · BMJ · doi:10.1136/bmj.1.5750.640 · Cited by 60
Limited value of myeloablative therapy for late multiple myeloma
Alexanian, R., Dimopoulos, M. A., Smith, T., Delasalle, K. B., Barlogie, B., & Champlin, R. (1994) · Blood · doi:10.1182/blood.v83.2.512.512 · Cited by 59
Efficacy and outcome of autologous transplantation in rare myelomas
Morris, C., Drake, M. B., Apperley, J. F., Iacobelli, S., van Biezen, A., Björkstrand, B., Goldschmidt, H., Harousseau, J., Morgan, G. J., de Witte, T., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.022848 · Cited by 59
Self-citation
Cited by
Chapter 1: Definition and classification of CKD
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.64 · Cited by 1,110
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
Terpos, E., Kleber, M., Engelhardt, M., Zweegman, S., Gay, F., Kastritis, E., van de Donk, N. W. C. J., Bruno, B., Sezer, O., Broijl, A., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.117176 · Cited by 988
Mikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., Dispenzieri, A., Fonseca, R., Sher, T., Kyle, R. A., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.019 · Cited by 500
Palumbo, A., Rajkumar, S. V., San Miguel, J. F., Larocca, A., Niesvizky, R., Morgan, G., Landgren, O., Hajek, R., Einsele, H., Anderson, K. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7934 · Cited by 392
Self-citationHuang, S.-Y., Lin, C.-W., Lin, H.-H., Yao, M., Tang, J.-L., Wu, S.-J., Chen, Y.-C., Lu, H.-Y., Hou, H.-A., Chen, C.-Y., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2063-7 · Cited by 62
Metadata
- Authors
- Bird, J. M., Owen, R. G., D’Sa, S., Snowden, J. A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., Morgan, G., Cavenagh, J., Low, E., Behrens, J., & on behalf of the Haemato‐oncology Task Force of the British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2011-05-14
- Volume
- 154
- Issue
- 1
- Pages
- 32-75
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1594485137
- Cited by
- 306
- References
- 238
- FWCI
- 24.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.